Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.
Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its ...
The CEO of Google Mind has suggested clinical trials of the first drugs designed with the help of AI could begin this year.
Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg ...
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.
Servier, an independent international pharmaceutical group, and Google Cloud have announced an expanded five-year partnership ...
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...
Every Cure researchers use Google Cloud's infrastructure to stay at the cutting edge of drug repurposing, an approach that can bypass the prolonged timelines and high costs associated with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback